Efficacy and safety levels of preserved and preservative-free tafluprost are equivalent in patients with glaucoma or ocular hypertension: results from a pharmacodynamics analysis.
about
Clinical appraisal of tafluprost in the reduction of elevated intraocular pressure (IOP) in open-angle glaucoma and ocular hypertensionClinical utility and differential effects of prostaglandin analogs in the management of raised intraocular pressure and ocular hypertensionA randomized, controlled comparison of macroscopic conjunctival hyperemia in patients treated with bimatoprost 0.01% or vehicle who were previously controlled on latanoprostSwitching patients from preserved prostaglandin-analog monotherapy to preservative-free tafluprost.Effects of preservative-free tafluprost on tear film osmolarity, tolerability, and intraocular pressure in previously treated patients with open-angle glaucoma.Controversy: Is Benzalkonium Chloride Necessary in Antiglaucoma Drops?Benefits of switching from latanoprost to preservative-free tafluprost eye drops: a meta-analysis of two Phase IIIb clinical trialsPreservative-free tafluprost in the treatment of naive patients with glaucoma and ocular hypertension.Ocular Tolerability of Preservative-Free Tafluprost and Latanoprost: in vitro and in vivo Comparative Study.Effects of tafluprost treatment for 3 years in patients with normal-tension glaucoma.Comparison of the ocular tolerability of a latanoprost cationic emulsion versus conventional formulations of prostaglandins: an in vivo toxicity assayBimatoprost 0.01% vs bimatoprost 0.03%: a 12-month prospective trial of clinical and in vivo confocal microscopy in glaucoma patientsEmerging drugs for ocular hypertension.Tafluprost: a novel prostaglandin analog for treatment of glaucoma.Ophthalmic preservatives: focus on polyquaternium-1.Tafluprost for glaucoma.Tafluprost once daily for treatment of elevated intraocular pressure in patients with open-angle glaucoma.Ocular surface cytotoxicity and safety evaluation of tafluprost, a recently developed anti-glaucoma prostaglandin analog.Efficacy and safety of tafluprost 0.0015% and timolol maleate 0.5% fixed combination in patients with ocular hypertension or open-angle glaucoma.Tafluprost/Timolol: A Review in Open-Angle Glaucoma or Ocular Hypertension.NOVELTIES IN MEDICAL TREATMENT OF GLAUCOMA.Tafluprost Ophthalmic Solution 0.0015 %: A Review in Glaucoma and Ocular Hypertension.The cytotoxic effects of preserved and preservative-free prostaglandin analogs on human corneal and conjunctival epithelium in vitro and the distribution of benzalkonium chloride homologs in ocular surface tissues in vivo.Tafluprost for the reduction of interocular pressure in open angle glaucoma and ocular hypertension.Changes in Ocular Surface Characteristics after Switching from Benzalkonium Chloride-Preserved Latanoprost to Preservative-Free Tafluprost or Benzalkonium Chloride-Preserved Tafluprost.Analysis of the effects of preservative-free tafluprost on the tear proteome.Safety and tolerability of tafluprost in treatment of elevated intraocular pressure in open-angle glaucoma and ocular hypertension.Efficacy and safety of tafluprost 0.0015% versus latanoprost 0.005% eye drops in open-angle glaucoma and ocular hypertension: 24-month results of a randomized, double-masked phase III study.Preservative-free tafluprost 0.0015% in the treatment of patients with glaucoma and ocular hypertension.Pharmacokinetics, efficacy and safety profiles of preserved and preservative-free tafluprost in healthy volunteers.In search of improved prostaglandin treatment for glaucoma.Acute corneal toxicity of latanoprost with different preservatives.Preservative-Free Prostaglandin Analogs and Prostaglandin/Timolol Fixed Combinations in the Treatment of Glaucoma: Efficacy, Safety and Potential Advantages.Efficacy and ocular surface tolerability of preservative-free tafluprost 0.0015%: a 6-month, single-blind, observational study on naïve ocular hypertension or glaucoma patients.Pharmacokinetics, Efficacy, and Safety of the Preservative-free Fixed Combination of Tafluprost 0.0015% and Timolol 0.5% in Healthy Volunteers: A Phase I Comparison vs. the Corresponding Preservative-free Monotherapies.Determination of preservatives in soft drinks by capillary electrophoresis with ionic liquids as the electrolyte additives.Patient stratification in clinical glaucoma trials using the individual tear proteomeA prospective study evaluating IOP changes after switching from a therapy with prostaglandin eye drops containing preservatives to nonpreserved tafluprost in glaucoma patients
P2860
Q33774236-15812537-985D-429D-8737-BD6317EF9A75Q34043309-36FF930D-CE15-4C76-A40A-D88479E2E629Q34399842-1CD3B0BE-E48F-4B28-BE56-D33A85976DE3Q35015841-45BBE5D2-EF9B-4B75-9F22-F581E1F37DE2Q35682054-88CB2A53-C714-4310-8445-3C39B63856FCQ36543265-CA7FABFA-4475-4F83-AACA-7DE24E846093Q36710059-160022FA-9BE6-472E-B060-4A0FB60727E3Q36873329-F4FB5B7C-A6A5-46D8-8E93-FBFB1657D0EBQ36985297-4A149DE9-17B7-4270-A4F6-CB50B43E0E5CQ37014469-E09DF4EA-5FC9-4D64-88BF-C81C625CB456Q37318278-5FF45757-CB31-4B3B-BDF5-C6601707CE9AQ37697869-782F4492-9E32-4BF7-BF23-226C5958BFF9Q37847182-640FB948-9B7C-4AEE-A662-9D366CE1E982Q37920765-32C0810C-94CD-43B4-B15E-CBBAC91724AAQ37929746-111D2A23-35B2-4A8D-92DA-4245D7A8E031Q37931967-11234F61-B5A2-4D28-9DFA-6CC25910D490Q38072028-5FED769E-93FC-4798-A238-8B1B1ED21940Q38190054-E62BD474-631B-4901-9FF4-E179DAD4854AQ38244537-3E255D54-ACD6-4462-BBF0-68484886B959Q38598001-52362303-7635-446D-955A-98BF3B54B197Q38775479-CA2FEE28-CE71-4160-9190-942C55380A14Q38844472-0E8F37F2-6960-4FEB-B255-C6F50F2817DFQ39448716-B865BFCB-D46C-4366-B034-4458DB9B12EDQ40938971-F65C2FC5-0321-43D2-9CC0-DCA68C7CD054Q41431150-17FAC326-0113-49D9-BC4B-23717FEC9D8BQ41668980-6B4B5780-C831-4BE7-91EC-F4C89B962964Q41911324-EAB34141-BCC5-49B6-8A53-18856E43605AQ43085229-D2483DD4-D7FA-47D8-A373-26A8A18AC4FCQ45375394-204F84E7-EDEB-4781-BFEB-22E507AD7A0BQ46407919-A3E87C97-7ED3-4DFA-9CA6-451BB2E3725FQ46407921-DE82AE8F-8E3E-45DF-A014-635B649105A1Q46715705-FE4DAB70-558B-4EC8-BD0D-B4B7874BC430Q47381165-E89F34FB-EAD9-4780-BEE0-F53C918DBEEEQ48429820-9B8504E9-F3DB-4DF6-93A2-FF5FF7471C31Q53343133-36A3A24B-CA63-4438-844F-2BB46163E295Q53530744-6FF615F9-3904-4DD9-9B98-E8F49F7D4732Q57214606-AB78E111-0876-4B11-B98C-33BD0E11AECBQ58915054-B78C8F71-E46B-458B-B647-76A4408E89A4
P2860
Efficacy and safety levels of preserved and preservative-free tafluprost are equivalent in patients with glaucoma or ocular hypertension: results from a pharmacodynamics analysis.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Efficacy and safety levels of ...... m a pharmacodynamics analysis.
@en
Efficacy and safety levels of ...... m a pharmacodynamics analysis.
@nl
type
label
Efficacy and safety levels of ...... m a pharmacodynamics analysis.
@en
Efficacy and safety levels of ...... m a pharmacodynamics analysis.
@nl
prefLabel
Efficacy and safety levels of ...... m a pharmacodynamics analysis.
@en
Efficacy and safety levels of ...... m a pharmacodynamics analysis.
@nl
P2093
P2860
P1476
Efficacy and safety levels of ...... m a pharmacodynamics analysis.
@en
P2093
M Johanna Liinamaa
Thomas Hamacher
Ulrich Richter
Ville Saarela
P2860
P356
10.1111/J.1755-3768.2008.01381.X
P577
2008-01-01T00:00:00Z